Stockwatch: All that glisters is not predictable
This article was originally published in Scrip
Dendreon’s restructuring announced on September 8, came after the disappointing second quarter sales of its bespoke prostate cancer vaccine Provenge (sipuelcel-T) which also resulted in the company’s sales guidance for the year being withdrawn (scripintelligence.com, 8 September 2011). It now appears that Dendreon’s woes might be a wake-up call, not just for investors who are also watching new product launches this year from other companies, but also the Securities and Exchange Commission (SEC) on disclosure policies and so-called black-out periods when company management is prevented from selling stock.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.